Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Redmond Surfs To WebMD, With Consumer Health Future In Mind

This article was originally published in The Tan Sheet

Executive Summary

Cavan Redmond left his role as Pfizer group president, with responsibility for consumer healthcare, to become CEO of the online health information provider May 31. The pharma veteran sees WebMD at the intersection of enabling consumers and physicians to make health care decisions.

You may also be interested in...



OTC Answers Website Plays Up Brands In Self-Selection Engine

Drug companies will have the opportunity to sponsor content categories and place products in the MyOTC recommendation engine on OTCAnswers.com. CEO Donald Blust wants the website to help boost branded products as they push back against private label.

OTC Answers Website Plays Up Brands In Self-Selection Engine

Drug companies will have the opportunity to sponsor content categories and place products in the MyOTC recommendation engine on OTCAnswers.com. CEO Donald Blust wants the website to help boost branded products as they push back against private label.

OTC Growth Will Not Find A Friend In Europe’s Financial Upheaval

As economic conditions tighten in Europe, former Pfizer exec Cavan Redmond expects consumers will spend less on OTCs while increasing their scrutiny of products and prices. Difficult economic conditions sharpen the constant necessity for OTC firms generate growth, he says.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel